Newburyport (MA, USA) – On Wednesday, February 28, 2024, AdvancedDx Biological Laboratories USA Inc., the US affiliate of ABL Diagnostics (FR001400AHX6 – ABLD), a Euronext-listed French company, announced the launch of a comprehensive Next Generation Sequencing (NGS) kit for HIV Whole Genome genotyping.
The DeepChek® Assay Whole Genome HIV-1 Genotyping has been developed to screen genomic variations in all HIV-1 genome genes targeted by current and under development HIV-1 inhibitors. This assay is designed for use with the leading NGS platforms and includes optimized multiplex PCR master mixes with primers to amplify RNA and proviral DNA inputs. It also offers manual or automated library preparations.
This comprehensive kit is intended for use in discovering and developing medical knowledge related to HIV-1 mutations prevalence and emergence and their possible impact of drug resistance. It screens for mutations on all HIV-1 genomic targets related to HIV-1 inhibitors, including new drugs like lenacapavir and cabenuva.
Dimitri Gonzalez, Head of Sales & Marketing, explained that “there is a trend for microbiology laboratories to further implement NGS-based technologies in addition to traditional capillary electrophoresis (Sanger) sequencing. Our portfolio should fulfill laboratories in the USA to work on new research projects, such as epidemiological studies related to mutations linked to HIV-1 capsid or entry inhibitors.”
ABL Diagnostics offers an array of Research Use Only kits for use on NGS platforms and some on Sanger sequencing platforms. This offer includes general laboratory product (GLP) reagents that enable diverse sequencing methods for a variety of sample types and throughput needs. DeepChek® library preparation reagents and universal adapters are for next generation sequencing.
The company also offers specific downstream sequencing analysis software, such as DeepChek® Software, to reduce laboratory staff burden and alleviate the need for specialized bioinformatics expertise. Alternatively, generic bioinformatics software and tools can be used for more advanced research teams.
ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). Its US affiliate, AdvancedDx Biological Laboratories USA, is based in Newburyport, Massachusetts, with warehouse facilities in Fairfield, New Jersey.
For further information, please visit www.abldx.com.
CONTACTS
ABL Diagnostics / AdvancedDx Biological Laboratories USA
Dr. Chalom Sayada
CEO
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the website of ABL Diagnostics (www.abldiagnostics.com) and to the development of economic conditions, financial markets and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of ABL Diagnostics to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
